The genomic landscape of metastasis in treatment-naïve breast cancer models

Autoři: Christina Ross aff001;  Karol Szczepanek aff001;  Maxwell Lee aff002;  Howard Yang aff002;  Tinghu Qiu aff001;  Jack Sanford aff001;  Kent Hunter aff001;  Jack D. Sanford aff001
Působiště autorů: Laboratory of Cancer Biology and Genetics, Metastasis Susceptibility Section, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America aff001;  Laboratory of Cancer Biology and Genetics, High-Dimension Data Analysis Group, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America aff002
Vyšlo v časopise: The genomic landscape of metastasis in treatment-naïve breast cancer models. PLoS Genet 16(5): e32767. doi:10.1371/journal.pgen.1008743
Kategorie: Research Article
doi: 10.1371/journal.pgen.1008743


Metastasis remains the principle cause of mortality for breast cancer and presents a critical challenge because secondary lesions are often refractory to conventional treatments. While specific genetic alterations are tightly linked to primary tumor development and progression, the role of genetic alteration in the metastatic process is not well-understood. The theory of tumor evolution postulated by Peter Nowell in 1976 has yet to be proven in the context of metastasis. Therefore, in order to investigate how somatic evolution contributes to breast cancer metastasis, we performed exome, whole genome, and RNA sequencing of matched metastatic and primary tumors from pre-clinical mouse models of breast cancer. Here we show that in a treatment-naïve setting, recurrent single nucleotide variants and copy number variation, but not gene fusion events, play key metastasis-driving roles in breast cancer. For instance, we identified recurrent mutations in Kras, a known driver of colorectal and lung tumorigenesis that has not been previously implicated in breast cancer metastasis. However, in a set of in vivo proof-of-concept experiments we show that the Kras G12D mutation is sufficient to significantly promote metastasis using three syngeneic allograft models. The work herein confirms the existence of metastasis-driving mutations and presents a novel framework to identify actionable metastasis-targeted therapies.

Klíčová slova:

Breast cancer – Comparative genomics – Genome annotation – Mammalian genomics – Metastasis – Metastatic tumors – Mouse models – RNA sequencing


1. Sonnenblick A, Pondé N, Piccart M. Metastatic breast cancer: The Odyssey of personalization. Mol Oncol. 2016;10: 1147–1159. doi: 10.1016/j.molonc.2016.07.002 27430154

2. Female Breast Cancer—Cancer Stat Facts [Internet]. [cited 11 Apr 2018]. Available:

3. Mattson J, Huovinen R. [Treatment of disseminated breast cancer]. Duodecim. 2015;131: 1033–1040.

4. Rachdi H, Mokrani A, Batti R, Ayadi M, Chraiet N, Mezlini A. Target therapy for metastatic breast cancer. Tunis Med. 2018;96: 465–471.

5. Steeg PS. Targeting metastasis. Nat Rev Cancer. 2016;16: 201–218. doi: 10.1038/nrc.2016.25 27009393

6. Lu J, Steeg PS, Price JE, Krishnamurthy S, Mani SA, Reuben J, et al. Breast cancer metastasis: challenges and opportunities. Cancer Res. 2009;69: 4951–4953. doi: 10.1158/0008-5472.CAN-09-0099 19470768

7. Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194: 23–28. doi: 10.1126/science.959840 959840

8. Hunter KW, Amin R, Deasy S, Ha N-H, Wakefield L. Genetic insights into the morass of metastatic heterogeneity. Nat Rev Cancer. 2018;18: 211–223. doi: 10.1038/nrc.2017.126 29422598

9. Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15: 81–94. doi: 10.1038/nrclinonc.2017.166 29115304

10. Alizadeh AA, Aranda V, Bardelli A, Blanpain C, Bock C, Borowski C, et al. Toward understanding and exploiting tumor heterogeneity. Nat Med. 2015;21: 846–853. doi: 10.1038/nm.3915 26248267

11. Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature. 2013;501: 328–337. doi: 10.1038/nature12624 24048065

12. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490: 61–70. doi: 10.1038/nature11412 23000897

13. Faraji F, Hu Y, Yang HH, Lee MP, Winkler GS, Hafner M, et al. Post-transcriptional Control of Tumor Cell Autonomous Metastatic Potential by CCR4-NOT Deadenylase CNOT7. PLoS Genet. 2016;12: e1005820. doi: 10.1371/journal.pgen.1005820 26807845

14. Ha N-H, Long J, Cai Q, Shu XO, Hunter KW. The Circadian Rhythm Gene Arntl2 Is a Metastasis Susceptibility Gene for Estrogen Receptor-Negative Breast Cancer. PLoS Genet. 2016;12: e1006267. doi: 10.1371/journal.pgen.1006267 27656887

15. Gilkes DM, Semenza GL, Wirtz D. Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat Rev Cancer. 2014;14: 430–439. doi: 10.1038/nrc3726 24827502

16. Chaffer CL, San Juan BP, Lim E, Weinberg RA. EMT, cell plasticity and metastasis. Cancer Metastasis Rev. 2016;35: 645–654. doi: 10.1007/s10555-016-9648-7 27878502

17. Patel SA, Vanharanta S. Epigenetic determinants of metastasis. Mol Oncol. 2017;11: 79–96. doi: 10.1016/j.molonc.2016.09.008 27756687

18. Hosseini H, Obradović MMS, Hoffmann M, Harper KL, Sosa MS, Werner-Klein M, et al. Early dissemination seeds metastasis in breast cancer. Nature. 2016;540: 552–558. doi: 10.1038/nature20785 27974799

19. Linde N, Casanova-Acebes M, Sosa MS, Mortha A, Rahman A, Farias E, et al. Macrophages orchestrate breast cancer early dissemination and metastasis. Nat Commun. 2018;9: 21. doi: 10.1038/s41467-017-02481-5 29295986

20. Harper KL, Sosa MS, Entenberg D, Hosseini H, Cheung JF, Nobre R, et al. Mechanism of early dissemination and metastasis in Her2+ mammary cancer. Nature. 2016;540: 588–592. doi: 10.1038/nature20609 27974798

21. Pfefferle AD, Herschkowitz JI, Usary J, Harrell JC, Spike BT, Adams JR, et al. Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts. Genome Biol. 2013;14: R125. doi: 10.1186/gb-2013-14-11-r125 24220145

22. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol. 1992;12: 954–961. doi: 10.1128/MCB.12.3.954 1312220

23. Goddard KAB, Weinmann S, Richert-Boe K, Chen C, Bulkley J, Wax C. HER2 evaluation and its impact on breast cancer treatment decisions. Public Health Genomics. 2012;15: 1–10. doi: 10.1159/000325746 21540562

24. Yaziji H, Goldstein LC, Barry TS, Werling R, Hwang H, Ellis GK, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA. 2004;291: 1972–1977. doi: 10.1001/jama.291.16.1972 15113815

25. Millis SZ, Ikeda S, Reddy S, Gatalica Z, Kurzrock R. Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors. JAMA Oncol. 2016;2: 1565–1573. doi: 10.1001/jamaoncol.2016.0891 27388585

26. Liu Y, Patel L, Mills GB, Lu KH, Sood AK, Ding L, et al. Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. J Natl Cancer Inst. 2014;106. doi: 10.1093/jnci/dju245 25214561

27. Faraji F, Pang Y, Walker RC, Nieves Borges R, Yang L, Hunter KW. Cadm1 is a metastasis susceptibility gene that suppresses metastasis by modifying tumor interaction with the cell-mediated immunity. PLoS Genet. 2012;8: e1002926. doi: 10.1371/journal.pgen.1002926 23028344

28. Lancaster M, Rouse J, Hunter KW. Modifiers of mammary tumor progression and metastasis on mouse chromosomes 7, 9, and 17. Mamm Genome. 2005;16: 120–126.

29. Le Voyer T, Rouse J, Lu Z, Lifsted T, Williams M, Hunter KW. Three loci modify growth of a transgene-induced mammary tumor: suppression of proliferation associated with decreased microvessel density. Genomics. 2001;74: 253–261. doi: 10.1006/geno.2001.6562 11414753

30. McLean CY, Bristor D, Hiller M, Clarke SL, Schaar BT, Lowe CB, et al. GREAT improves functional interpretation of cis-regulatory regions. Nat Biotechnol. 2010;28: 495–501. doi: 10.1038/nbt.1630 20436461

31. Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016;534: 47–54. doi: 10.1038/nature17676 27135926

32. McPherson A, Hormozdiari F, Zayed A, Giuliany R, Ha G, Sun MGF, et al. deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. PLoS Comput Biol. 2011;7: e1001138. doi: 10.1371/journal.pcbi.1001138 21625565

33. Fan X, Abbott TE, Larson D, Chen K. BreakDancer: Identification of Genomic Structural Variation from Paired-End Read Mapping. Curr Protoc Bioinformatics. 2014;45: 15.6.1–11. doi: 10.1002/0471250953.bi1506s45 25152801

34. Yang Y, Yang HH, Hu Y, Watson PH, Liu H, Geiger TR, et al. Immunocompetent mouse allograft models for development of therapies to target breast cancer metastasis. Oncotarget. 2017;8: 30621–30643. doi: 10.18632/oncotarget.15695 28430642

35. Alzubi MA, Turner TH, Olex AL, Sohal SS, Tobin NP, Recio SG, et al. Separation of breast cancer and organ microenvironment transcriptomes in metastases. Breast Cancer Res. 2019;21: 36. doi: 10.1186/s13058-019-1123-2 30841919

36. Shao DD, Xue W, Krall EB, Bhutkar A, Piccioni F, Wang X, et al. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell. 2014;158: 171–184. doi: 10.1016/j.cell.2014.06.004 24954536

37. Kim R-K, Suh Y, Yoo K-C, Cui Y-H, Kim H, Kim M-J, et al. Activation of KRAS promotes the mesenchymal features of basal-type breast cancer. Exp Mol Med. 2015;47: e137. doi: 10.1038/emm.2014.99 25633745

38. Hollern DP, Swiatnicki MR, Andrechek ER. Histological subtypes of mouse mammary tumors reveal conserved relationships to human cancers. PLoS Genet. 2018;14: e1007135. doi: 10.1371/journal.pgen.1007135 29346386

39. Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20: 69–84. doi: 10.1038/s41580-018-0080-4 30459476

40. Hoefnagel LDC, van der Groep P, van de Vijver MJ, Boers JE, Wesseling P, Wesseling J, et al. Discordance in ERα, PR and HER2 receptor status across different distant breast cancer metastases within the same patient. Ann Oncol. 2013;24: 3017–3023. doi: 10.1093/annonc/mdt390 24114857

41. Bell R, Barraclough R, Vasieva O. Gene Expression Meta-Analysis of Potential Metastatic Breast Cancer Markers. Curr Mol Med. 2017;17: 200–210. doi: 10.2174/1566524017666170807144946 28782484

42. Krøigård AB, Larsen MJ, Thomassen M, Kruse TA. Molecular concordance between primary breast cancer and matched metastases. Breast J. 2016;22: 420–430. doi: 10.1111/tbj.12596 27089067

43. Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature. 2010;464: 999–1005. doi: 10.1038/nature08989 20393555

44. Vakiani E, Janakiraman M, Shen R, Sinha R, Zeng Z, Shia J, et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol. 2012;30: 2956–2962. doi: 10.1200/JCO.2011.38.2994 22665543

45. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol. 2003;163: 2113–2126. doi: 10.1016/S0002-9440(10)63568-7 14578209

46. Kuukasjärvi T, Karhu R, Tanner M, Kähkönen M, Schäffer A, Nupponen N, et al. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res. 1997;57: 1597–1604.

47. De Mattos-Arruda L, Sammut S-J, Ross EM, Bashford-Rogers R, Greenstein E, Markus H, et al. The genomic and immune landscapes of lethal metastatic breast cancer. Cell Rep. 2019;27: 2690–2708.e10. doi: 10.1016/j.celrep.2019.04.098 31141692

48. Echeverria GV, Powell E, Seth S, Ge Z, Carugo A, Bristow C, et al. High-resolution clonal mapping of multi-organ metastasis in triple negative breast cancer. Nat Commun. 2018;9: 5079. doi: 10.1038/s41467-018-07406-4 30498242

49. Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, et al. The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell. 2018;34: 427–438.e6. doi: 10.1016/j.ccell.2018.08.008 30205045

50. Yates LR, Knappskog S, Wedge D, Farmery JHR, Gonzalez S, Martincorena I, et al. Genomic evolution of breast cancer metastasis and relapse. Cancer Cell. 2017;32: 169–184.e7. doi: 10.1016/j.ccell.2017.07.005 28810143

51. Angus L, Smid M, Wilting SM, van Riet J, Van Hoeck A, Nguyen L, et al. The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies. Nat Genet. 2019;51: 1450–1458. doi: 10.1038/s41588-019-0507-7 31570896

52. Bertucci F, Ng CKY, Patsouris A, Droin N, Piscuoglio S, Carbuccia N, et al. Genomic characterization of metastatic breast cancers. Nature. 2019;569: 560–564. doi: 10.1038/s41586-019-1056-z 31118521

53. Nayar U, Cohen O, Kapstad C, Cuoco MS, Waks AG, Wander SA, et al. Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies. Nat Genet. 2019;51: 207–216. doi: 10.1038/s41588-018-0287-5 30531871

54. Pereira AAL, Rego JFM, Morris V, Overman MJ, Eng C, Garrett CR, et al. Association between KRAS mutation and lung metastasis in advanced colorectal cancer. Br J Cancer. 2015;112: 424–428. doi: 10.1038/bjc.2014.619 25535726

55. Jancík S, Drábek J, Radzioch D, Hajdúch M. Clinical relevance of KRAS in human cancers. J Biomed Biotechnol. 2010;2010: 150960. doi: 10.1155/2010/150960 20617134

56. Lièvre A, Bachet J-B, Le Corre D, Boige V, Landi B, Emile J-F, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66: 3992–3995. doi: 10.1158/0008-5472.CAN-06-0191 16618717

57. Sánchez-Muñoz A, Gallego E, de Luque V, Pérez-Rivas LG, Vicioso L, Ribelles N, et al. Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer. BMC Cancer. 2010;10: 136. doi: 10.1186/1471-2407-10-136 20385028

58. Wills MKB, Jones N. Teaching an old dogma new tricks: twenty years of Shc adaptor signalling. Biochem J. 2012;447: 1–16. doi: 10.1042/BJ20120769 22970934

59. D’Cruz CM, Gunther EJ, Boxer RB, Hartman JL, Sintasath L, Moody SE, et al. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med. 2001;7: 235–239. doi: 10.1038/84691 11175856

60. Campbell KM, O’Leary KA, Rugowski DE, Mulligan WA, Barnell EK, Skidmore ZL, et al. A spontaneous aggressive erα+ mammary tumor model is driven by kras activation. Cell Rep. 2019;28: 1526–1537.e4. doi: 10.1016/j.celrep.2019.06.098 31390566

61. Liu H, Murphy CJ, Karreth FA, Emdal KB, White FM, Elemento O, et al. Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer. Cancer Discov. 2018;8: 354–369. doi: 10.1158/2159-8290.CD-17-0679 29203461

62. Jeong W-J, Ro EJ, Choi K-Y. Interaction between Wnt/β-catenin and RAS-ERK pathways and an anti-cancer strategy via degradations of β-catenin and RAS by targeting the Wnt/β-catenin pathway. npj Precision Onc. 2018;2: 5. doi: 10.1038/s41698-018-0049-y 29872723

63. Malek JA, Mery E, Mahmoud YA, Al-Azwani EK, Roger L, Huang R, et al. Copy number variation analysis of matched ovarian primary tumors and peritoneal metastasis. PLoS One. 2011;6: e28561. doi: 10.1371/journal.pone.0028561 22194851

64. Behring M, Shrestha S, Manne U, Cui X, Gonzalez-Reymundez A, Grueneberg A, et al. Integrated landscape of copy number variation and RNA expression associated with nodal metastasis in invasive ductal breast carcinoma. Oncotarget. 2018;9: 36836–36848. doi: 10.18632/oncotarget.26386 30627325

65. Kutilin DS, Leyman IA, Lazutin YN, Chubaryan AV, Anistratov PA, Stateshny ON, et al. Genes copy number variation in tumor cells of patients with metastatic and non-metastatic lung adenocarcinoma. J Clin Oncol. 2019;37: e14502–e14502. doi: 10.1200/JCO.2019.37.15_suppl.e14502

66. Van Loo P, Nordgard SH, Lingjærde OC, Russnes HG, Rye IH, Sun W, et al. Allele-specific copy number analysis of tumors. Proc Natl Acad Sci USA. 2010;107: 16910–16915. doi: 10.1073/pnas.1009843107 20837533

67. El Gammal AT, Brüchmann M, Zustin J, Isbarn H, Hellwinkel OJC, Köllermann J, et al. Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer. Clin Cancer Res. 2010;16: 56–64. doi: 10.1158/1078-0432.CCR-09-1423 20028754

68. Sato K, Qian J, Slezak JM, Lieber MM, Bostwick DG, Bergstralh EJ, et al. Clinical Significance of Alterations of Chromosome 8 in High-Grade, Advanced, Nonmetastatic Prostate Carcinoma. JNCI Journal of the National Cancer Institute. 1999;91: 1574–1580. doi: 10.1093/jnci/91.18.1574 10491435

69. Kang JU. Chromosome 8q as the most frequent target for amplification in early gastric carcinoma. Oncol Lett. 2014;7: 1139–1143. doi: 10.3892/ol.2014.1849 24944681

70. Beuten J, Gelfond JAL, Martinez-Fierro ML, Weldon KS, Crandall AC, Rojas-Martinez A, et al. Association of chromosome 8q variants with prostate cancer risk in Caucasian and Hispanic men. Carcinogenesis. 2009;30: 1372–1379. doi: 10.1093/carcin/bgp148 19528667

71. Bilal E, Vassallo K, Toppmeyer D, Barnard N, Rye IH, Almendro V, et al. Amplified loci on chromosomes 8 and 17 predict early relapse in ER-positive breast cancers. PLoS One. 2012;7: e38575. doi: 10.1371/journal.pone.0038575 22719901

72. Yong ZWE, Zaini ZM, Kallarakkal TG, Karen-Ng LP, Rahman ZAA, Ismail SM, et al. Genetic alterations of chromosome 8 genes in oral cancer. Sci Rep. 2014;4: 6073. doi: 10.1038/srep06073 25123227

73. Weiss L. Dynamic aspects of cancer cell populations in metastasis. Am J Pathol. 1979;97: 601–608.

74. van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AAM, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347: 1999–2009. doi: 10.1056/NEJMoa021967 12490681

75. Baudot A, Real FX, Izarzugaza JMG, Valencia A. From cancer genomes to cancer models: bridging the gaps. EMBO Rep. 2009;10: 359–366. doi: 10.1038/embor.2009.46 19305388

76. Fugmann RA, Anderson JC, Stolfi RL, Martin DS. Comparison of adjuvant chemotherapeutic activity against primary and metastatic spontaneous murine tumors. Cancer Res. 1977;37: 496–500.

77. Yuan TL, Fellmann C, Lee C-S, Ritchie CD, Thapar V, Lee LC, et al. Development of siRNA payloads to target KRAS-mutant cancer. Cancer Discov. 2014;4: 1182–1197. doi: 10.1158/2159-8290.CD-13-0900 25100204

Genetika Reprodukční medicína

Článek vyšel v časopise

PLOS Genetics

2020 Číslo 5

Nejčtenější v tomto čísle

Tomuto tématu se dále věnují…

Kurzy Doporučená témata Časopisy
Zapomenuté heslo

Nemáte účet?  Registrujte se

Zapomenuté heslo

Zadejte e-mailovou adresu se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.


Nemáte účet?  Registrujte se

VIRTUÁLNÍ ČEKÁRNA ČR Jste praktický lékař nebo pediatr? Zapojte se! Jste praktik nebo pediatr? Zapojte se!